Details of the Drug
General Information of Drug (ID: DM1CB5J)
| Drug Name |
2-Benzyl-1,2-dihydro-indazol-3-one
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
2-Benzyl-1,2-dihydro-indazol-3-one; 1848-46-0; CHEMBL1984519; NSC34822; 2-benzyl-1H-indazol-3-one; SCHEMBL9645952; CHEMBL267523; AC1L91I6; CTK4D8835; DTXSID40328538; 2-Benzyl-1H-indazol-3(2H)-one; ZINC1667231; NSC-34822; BDBM50009000; AKOS015963502; FCH2821694; ACM1848460; NCI60_003094
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 224.26 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.8 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


